![Relazione tra anticipazione diagnostica e terapie: confronto fra cancri della mammella in donne sottoposte e non a screening Relazione tra anticipazione diagnostica e terapie: confronto fra cancri della mammella in donne sottoposte e non a screening](https://www.epicentro.iss.it/ben/2018/novembre/tab2-2.png)
Relazione tra anticipazione diagnostica e terapie: confronto fra cancri della mammella in donne sottoposte e non a screening
![Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China - Xue - 2012 - Cancer Science - Wiley Online Library Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China - Xue - 2012 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/612cef35-5f64-4f12-b8ff-3bae982283b9/cas2339-fig-0002-m.jpg)
Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China - Xue - 2012 - Cancer Science - Wiley Online Library
Scholarly Article or Book Chapter | Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | ID: h989r975x | Carolina Digital Repository
![Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/2-Table1-1.png)
Table 1 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
Progesterone Receptor Status and Ki-67 Index May Predict Early Relapse in Luminal B/HER2 Negative Breast Cancer Patients: A Retrospective Study | PLOS ONE
![MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs13000-022-01209-4/MediaObjects/13000_2022_1209_Fig1_HTML.png)
MCM6 versus Ki-67 in diagnosis of luminal molecular subtypes of breast cancers | Diagnostic Pathology | Full Text
![Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis](https://www.frontiersin.org/files/Articles/813462/fonc-12-813462-HTML-r1/image_m/fonc-12-813462-g001.jpg)
Frontiers | Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
![การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology](https://www.asianarchpath.com/storage/AAP_Technical_V2N1_2020/AAP_Technical_V2N1_2020.png)
การแบ่งประเภททางโมเลกุลของมะเร็งเต้านม (Molecular classification of breast cancer) | Asian Archives of Pathology
![Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC](https://europepmc.org/articles/PMC4863770/bin/medi-95-e3518-g001.jpg)
Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population. - Abstract - Europe PMC
![Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal](https://www.emjreviews.com/wp-content/uploads/2020/11/Figure-1-Concordance-between-immunohistochemistry-and-PAM50-using-two-different-cut-off-values.jpg)
Identifying the Best Ki67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification - European Medical Journal
![Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2F1756-0500-5-376/MediaObjects/13104_2011_Article_1552_Fig1_HTML.jpg)
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
![JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes](https://www.mdpi.com/jpm/jpm-12-01988/article_deploy/html/images/jpm-12-01988-g001-550.jpg)
JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
![Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fmodpathol.2013.153/MediaObjects/41379_2014_Article_BFmodpathol2013153_Fig2_HTML.jpg)
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
![PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a33aa443a365c6282bd5449f8899f125cb99c7a9/3-Table3-1.png)
PDF] Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information | Semantic Scholar
![Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors](https://www.spandidos-publications.com/article_images/ol/17/1/ol-17-01-0616-g00.jpg)
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study](https://pub.mdpi-res.com/cancers/cancers-14-02215/article_deploy/html/images/cancers-14-02215-ag.png?1651227522)
Cancers | Free Full-Text | An Invasive Disease Event-Free Survival Analysis to Investigate Ki67 Role with Respect to Breast Cancer Patients’ Age: A Retrospective Cohort Study
![PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/60a5e17db2ebec70ad7ebb9addd7b2a5f3bf9992/6-Figure1-1.png)
PDF] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer | Semantic Scholar
![Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors](https://www.spandidos-publications.com/article_images/ol/17/1/ol-17-01-0616-g03.jpg)
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
![Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram](https://www.researchgate.net/publication/357176278/figure/fig3/AS:1128655296167977@1646103800585/Expression-of-ER-PR-Her2-and-Ki-67-by-immunohistochemical-staining-in-luminal-A.png)
Expression of ER, PR, Her2, and Ki-67 by immunohistochemical staining... | Download Scientific Diagram
![Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fmodpathol.2013.153/MediaObjects/41379_2014_Article_BFmodpathol2013153_Fig1_HTML.jpg)
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
![Performance of Ki67 (as a continuous variable) to predict Luminal A or... | Download Scientific Diagram Performance of Ki67 (as a continuous variable) to predict Luminal A or... | Download Scientific Diagram](https://www.researchgate.net/publication/314233739/figure/fig3/AS:468551195729922@1488722718597/Performance-of-Ki67-as-a-continuous-variable-to-predict-Luminal-A-or-ROR-low-disease.png)
Performance of Ki67 (as a continuous variable) to predict Luminal A or... | Download Scientific Diagram
![The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score - Yang - 2023 - Cancer Medicine - Wiley Online Library The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score - Yang - 2023 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/b89d1844-41b2-4837-a4c5-574ccdc0c966/cam45089-fig-0001-m.jpg)